Jupiter Neurosciences cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 11 quarters of results from Sep 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Net Income | -1.52M | -0.64M | -0.64M | -0.61M | -0.60M | -1.48M | -1.53M | -2.25M | -2.29M | -2.87M | -2.82M |
| Share-based CompensationStock Comp. | 0.21M | 0.06M | 0.57M | 10.63M | 1.01M | 10.63M | 10.88M | 11.73M | 0.46M | 1.68M | |
| Cash from OperationsCash from Ops. | -0.16M | -0.07M | -0.11M | -0.04M | -3.70M | -1.06M | -0.83M | -1.15M | -2.37M | ||
| Depreciation, Depletion & Amortization | |||||||||||
| Amortizatization of IntangiblesAmort. of Intangibles | 0.01M | 0.00M | 0.00M | 0.01M | 0.03M | ||||||
| Change in Working Capital | |||||||||||
| Change in Accured ExpensesChange Accured Exp. | 0.24M | 0.18M | 0.18M | 0.18M | -0.69M | -0.11M | 0.56M | -0.01M | -0.19M | ||
| Other Working Capital ChangesOther WC Changes | 0.14M | -0.01M | |||||||||
| Financing Activities | |||||||||||
| Cash from Financing ActivitiesCash from Financing | 0.13M | 0.04M | 0.11M | 0.03M | 7.47M | ||||||
| Change in Capital Stock | |||||||||||
| Net Shares Issued and RepurchasedNet Shares Issued | 3.77M | 0.30M | 0.25M | 1.09M | |||||||
| Net Equity Issued and RepurchasedNet Equity Issued | 0.10M | ||||||||||
| Additional items | |||||||||||
| Change in Cash | -0.03M | -0.02M | 0.01M | -0.01M | 3.77M | -1.06M | -0.83M | -1.15M | 3.07M | ||
| Free Cash FlowFCF | -0.16M | -0.07M | -0.11M | -0.04M | -3.70M | -1.06M | -0.83M | -1.15M | -2.37M | ||
| Net Cash FlowNCF | -0.03M | -0.02M | 0.01M | -0.01M | 3.77M | -1.06M | -0.83M | -1.15M | -2.37M |